Spectral AI, Inc. Form 8-K Summary
Business Context and Reporting Period
Spectral AI, Inc. filed a Current Report on Form 8-K concerning corporate governance and investor disclosure matters. The report identifies February 7, 2024 as the date of the earliest reported event and was signed and furnished with a related press release on February 12, 2024. Spectral AI is listed on Nasdaq under the symbols MDAI and MDAIW.
Material Event
- The Board appointed Dr. J. Michael DiMaio as a director, effective immediately.
- Dr. DiMaio is a company founder and previously served as Chief Executive Officer and Chairman from 2011 to 2020.
- He currently serves as Chief of Staff and a practicing board-certified general, cardiac and thoracic surgeon at Baylor Scott & White—The Heart Hospitals.
- The filing states that he oversees more than 650 physicians across six facilities, approximately 25,000 cardiovascular procedures annually, and more than 120 clinical trials at the Baylor Scott & White Research Institute.
- His background includes nearly 500 peer-reviewed publications and abstracts, leadership in medical organizations, and participation as principal investigator in clinical trials involving FDA-approved drugs and devices.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, balance-sheet figures, or other operating financial metrics.
Changes, Outlook, Risks, and Unusual Items
- The principal change is the addition of a former chief executive and company founder to the Board.
- The filing notes that Dr. DiMaio exited his prior company positions in 2020 and amicably resolved a dispute that had arisen at that time.
- No financial guidance, operating outlook, material contingencies, or new risk factors are disclosed in the provided filing text.
- Item 7.01 and Exhibit 99.1 contain furnished, rather than filed, Regulation FD disclosure and are not incorporated by reference except as expressly stated in a subsequent filing.
Key Facts for Investors to Verify
- Confirm the effective date and scope of Dr. DiMaio’s Board appointment.
- Review the February 12, 2024 press release furnished as Exhibit 99.1.
- Assess any potential governance, related-party, or historical-dispute implications associated with his prior departure and return.
- Consult the company’s periodic financial filings for current financial performance, cash position, debt, liquidity, and guidance, none of which are provided here.